CNSide Diagnostics, a wholly-owned subsidiary of Plus Therapeutics, Inc. (NASDAQ: PSTV), has signed a national agreement with UnitedHealthcare insurance company, a unit of UnitedHealth Group Inc. (NYSE: UNH).

Effective September 15, the agreement covers over 51 million people throughout the United States, providing the CNSide Cerebrospinal Fluid (CSF) Tumor Cell Enumeration laboratory developed test (LDT).

The CNSide CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases.

The superior clinical utility of CNSide over standard of care has been shown in 9 peer-reviewed publications, the FORESEE clinical trial, and has been validated in the market through real-world use.

Also Read: